Abstract
Association of rifampicin with polybutylcyanoacrylate nanoparticles provided considerable enhancement of drug antibacterial activity. In vitro nanoparticle-loaded rifampicin was more active against Staphylococcus aureus and Mycobacterium avium, localized in isolated alveolar macrophages. Level of rifampicin in macrophages increased 2-3-fold after incubation with rifampicin-loaded nanoparticles comparing to the free drug. High therapeutic efficacy of colloidal rifampicin was demonstrated in vivo. Use of nanoparticles provided 2-fold increase in rifampicin efficacy, comparing with the free drug at treatment of staphylococcus sepsis in mice. Single administration of nanoparticulate rifampicin in the dose 25 mg/kg resulted in 80% survival of mice with salmonellosis, while 50 mg/kg of free rifampicin could provide only 10% survival. It may be considered that high antibacterial efficacy of rifampicin bound to nanoparticles is due to its effective delivery to macrophages.
| Original language | English |
|---|---|
| Pages (from-to) | 23-26 |
| Number of pages | 4 |
| Journal | Antibiotiki i Khimioterapiya |
| Volume | 48 |
| Issue number | 1 |
| Publication status | Published - 2003 |
| Externally published | Yes |
Fingerprint
Keywords
- Alveolar macrophages
- Antibacterial activity
- Nanoparticles
- Rifampicin
ASJC Scopus subject areas
- Microbiology
- Pharmacology
Cite this
Enhanced antibacterial activity of rifampicin associated with biodegradable polybutylcyanoacrylate nanoparticles. / Skidan, I. N.; Gelperina, S. E.; Severin, S. E.; Gulyaev, A. E.
In: Antibiotiki i Khimioterapiya, Vol. 48, No. 1, 2003, p. 23-26.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Enhanced antibacterial activity of rifampicin associated with biodegradable polybutylcyanoacrylate nanoparticles
AU - Skidan, I. N.
AU - Gelperina, S. E.
AU - Severin, S. E.
AU - Gulyaev, A. E.
PY - 2003
Y1 - 2003
N2 - Association of rifampicin with polybutylcyanoacrylate nanoparticles provided considerable enhancement of drug antibacterial activity. In vitro nanoparticle-loaded rifampicin was more active against Staphylococcus aureus and Mycobacterium avium, localized in isolated alveolar macrophages. Level of rifampicin in macrophages increased 2-3-fold after incubation with rifampicin-loaded nanoparticles comparing to the free drug. High therapeutic efficacy of colloidal rifampicin was demonstrated in vivo. Use of nanoparticles provided 2-fold increase in rifampicin efficacy, comparing with the free drug at treatment of staphylococcus sepsis in mice. Single administration of nanoparticulate rifampicin in the dose 25 mg/kg resulted in 80% survival of mice with salmonellosis, while 50 mg/kg of free rifampicin could provide only 10% survival. It may be considered that high antibacterial efficacy of rifampicin bound to nanoparticles is due to its effective delivery to macrophages.
AB - Association of rifampicin with polybutylcyanoacrylate nanoparticles provided considerable enhancement of drug antibacterial activity. In vitro nanoparticle-loaded rifampicin was more active against Staphylococcus aureus and Mycobacterium avium, localized in isolated alveolar macrophages. Level of rifampicin in macrophages increased 2-3-fold after incubation with rifampicin-loaded nanoparticles comparing to the free drug. High therapeutic efficacy of colloidal rifampicin was demonstrated in vivo. Use of nanoparticles provided 2-fold increase in rifampicin efficacy, comparing with the free drug at treatment of staphylococcus sepsis in mice. Single administration of nanoparticulate rifampicin in the dose 25 mg/kg resulted in 80% survival of mice with salmonellosis, while 50 mg/kg of free rifampicin could provide only 10% survival. It may be considered that high antibacterial efficacy of rifampicin bound to nanoparticles is due to its effective delivery to macrophages.
KW - Alveolar macrophages
KW - Antibacterial activity
KW - Nanoparticles
KW - Rifampicin
UR - http://www.scopus.com/inward/record.url?scp=0037968388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037968388&partnerID=8YFLogxK
M3 - Article
C2 - 12741319
AN - SCOPUS:0037968388
VL - 48
SP - 23
EP - 26
JO - Antibiotiki i Khimioterapiya
JF - Antibiotiki i Khimioterapiya
SN - 0235-2990
IS - 1
ER -